Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CITIUS ONCOLOGY, INC.CTOR · Entity 6935 | Director | September 19, 2025 | December 22, 2025 |
| Peace Acquisition Corp.PECE · Entity 6873 | Director | May 21, 2026 | May 21, 2026 |
| TELIX QSAM INC.QSAM · Entity 91566 | Director | December 31, 2021 | February 14, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CITIUS ONCOLOGY, INC.
Report date September 19, 2025 · Filed December 22, 2025 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 321,228 |
Reported balance
After 2025-09-19 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2025-09-19 · Grant · Acquired 300,000 · Balance 321,228 F1: Represents restricted stock units granted on September 19, 2025. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units granted on September 19, 2025. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
Peace Acquisition Corp.
Report date May 21, 2026 · Filed May 21, 2026
This filing explicitly reported no securities owned.
TELIX QSAM INC.
Report date December 31, 2021 · Filed February 14, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 400,000 |
Reported balance
After 2021-12-15 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2021-12-15 · Grant · Acquired 400,000 · Balance 400,000 F1: This award of shares was made pursuant to Issuer's board of director's approval under Issuer's restricted stock agreement. |
| COMMON STOCKSEC Table I · non-derivative | Direct | 428,616 |
Reported balance
Holding disclosure · report date 2021-12-31 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 428,616 F2: The total holdings reported on previous Form 5 accidentally included 39,760 shares of common stock that Mr. Mayersohn did not hold. |
| Options to buy common stockSEC Table II · derivative / convertible security · Conversion / exercise price $0.36 · Expires 2031-08-23 | Direct | 54,000 |
Reported balance
After 2021-08-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-08-24 · Grant · Acquired 54,000 · Balance 54,000 F3: The options vest semi-annually in two equal installments beginning on 02/24/2022. |
| Options to buy common stockSEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2028-12-01 | Direct | 37,840 |
Reported balance
Holding disclosure · report date 2021-12-31 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 37,840 F4: The total holdings reported on previous Form 5 accidentally reported 2000 less options to buy common stock of the Company. |
| Options to buy common stockSEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2030-01-06 | Direct | 40,000 |
Reported balance
Holding disclosure · report date 2021-12-31 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 40,000 |
Filing footnotes · ownership attribution and instrument terms
F1: This award of shares was made pursuant to Issuer's board of director's approval under Issuer's restricted stock agreement.
F2: The total holdings reported on previous Form 5 accidentally included 39,760 shares of common stock that Mr. Mayersohn did not hold.
F3: The options vest semi-annually in two equal installments beginning on 02/24/2022.
F4: The total holdings reported on previous Form 5 accidentally reported 2000 less options to buy common stock of the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 19, 2025 Filed Sep 23, 2025 20:10 UTC | CITIUS ONCOLOGY, INC. CTOR · Entity 6935 | GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-090608 · ownership.xml · nonDerivative · entry 1 Mayersohn Joel David · CIK 0001588395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 321,228 F1 · shares: Represents restricted stock awards granted on September 19, 2025. The shares will vest in three substantially equal installments on the first, second and third anniversaries of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date. Read SEC document |
| September 19, 2025 Filed Dec 1, 2025 21:10 UTC Amendment | CITIUS ONCOLOGY, INC. CTOR · Entity 6935 | GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-116680 · ownership.xml · nonDerivative · entry 1 Mayersohn Joel David · CIK 0001588395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 321,228 F1 · shares: Represents restricted stock awards granted on September 19, 2025. The shares will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date. Read SEC document |
| September 19, 2025 Filed Dec 22, 2025 21:10 UTC Amendment | CITIUS ONCOLOGY, INC. CTOR · Entity 6935 | GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-124530 · ownership.xml · nonDerivative · entry 1 Mayersohn Joel David · CIK 0001588395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 321,228 F1 · shares: Represents restricted stock units granted on September 19, 2025. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date. Read SEC document |
| July 28, 2025 Filed Aug 7, 2025 21:02 UTC | CITIUS ONCOLOGY, INC. CTOR · Entity 6935 | OtherCommon Stock | 21,228 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-073136 · ownership.xml · nonDerivative · entry 1 Mayersohn Joel David · CIK 0001588395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,228 F1 · shares: The shares were acquired through a distribution in kind to limited partners of 10XYZ Holdings, which was the Sponsor of TenX Keane Acquisition ("TenX"), the legacy entity of Citius Oncology, Inc. Read SEC document |
| December 12, 2024 Filed Dec 16, 2024 22:05 UTC | CITIUS ONCOLOGY, INC. CTOR · Entity 6935 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001213900-24-109376 · ownership.xml · derivative · entry 1 Mayersohn Joel David · CIK 0001588395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2034-12-12 F1 · derivative.exercise_date: The options were granted on December 12, 2024. The options will vest 100% on the one-year anniversary of the grant date, provided that the Optionee provides Continuous Service to the Company as of the vesting date Read SEC document |
| December 15, 2021 Filed Feb 14, 2022 21:57 UTC | TELIX QSAM INC. QSAM · Entity 91566 | GrantCOMMON STOCK | 400,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-004618 · ownership.xml · nonDerivative · entry 1 Mayersohn Joel David · CIK 0001588395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 F1 · shares: This award of shares was made pursuant to Issuer's board of director's approval under Issuer's restricted stock agreement. Read SEC document |
| August 24, 2021 Filed Feb 14, 2022 21:57 UTC | TELIX QSAM INC. QSAM · Entity 91566 | GrantOptions to buy common stock · Derivative | 54,000 | $0.00 Strike: $0.36 | $0.00 |
DisclosureSEC source: 0001493152-22-004618 · ownership.xml · derivative · entry 3 Mayersohn Joel David · CIK 0001588395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,000 Underlying: Common Stock · 54,000 shares Expires 2031-08-23 F3 · derivative.exercise_date: The options vest semi-annually in two equal installments beginning on 02/24/2022. Read SEC document |
| December 17, 2020 Filed Feb 16, 2021 16:00 UTC | TELIX QSAM INC. QSAM · Entity 91566 | GrantCOMMON STOCK | 96,782 | $0.22 | $21,292.04 |
DisclosureSEC source: 0001493152-21-003961 · ownership.xml · nonDerivative · entry 2 Mayersohn Joel David · CIK 0001588395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 468,376 F2 · shares: Shares acquired upon conversion of accured directors fees at a conversion price of $0.22 per share. Read SEC document |
| September 30, 2020 Filed Feb 16, 2021 16:00 UTC | TELIX QSAM INC. QSAM · Entity 91566 | ConversionCOMMON STOCK | 331,834 | $0.22 | $73,003.48 |
DisclosureSEC source: 0001493152-21-003961 · ownership.xml · nonDerivative · entry 1 Mayersohn Joel David · CIK 0001588395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 371,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares acquired upon conversion of promissory note at a conversion price of $0.22 per share. Read SEC document |
| January 06, 2020 Filed Feb 16, 2021 16:00 UTC | TELIX QSAM INC. QSAM · Entity 91566 | GrantOptions to buy common stock · Derivative | 40,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001493152-21-003961 · ownership.xml · derivative · entry 4 Mayersohn Joel David · CIK 0001588395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: COMMON STOCK · 40,000 shares Expires 2030-01-06 Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 16:48 UTC | TELIX QSAM INC. QPWR · Entity 91566 | Purchaseoptions to purchase common stock · Derivative | 400,000 | $0.10 Strike: $0.10 | $40,000.00 |
DisclosureSEC source: 0001588395-18-000001 · primary_doc.xml · derivative · entry 1 Mayersohn Joel David · CIK 0001588395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 746,000 Underlying: common stock · 400,000 shares Expires 2018-06-01 F1 · derivative.exercise_date: 50% of options 06/01/2018 remaining 50% 12/01/2018 Read SEC document |
| December 28, 2016 Filed May 18, 2017 10:18 UTC | TELIX QSAM INC. qpwr · Entity 91566 | Purchaseoptions to purchase common stock · Derivative | 200,000 | $0.21 Strike: $0.21 | $42,000.00 |
DisclosureSEC source: 0001588395-17-000001 · primary_doc.xml · derivative · entry 2 Mayersohn Joel David · CIK 0001588395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: common stock · 200,000 shares Expires 2027-06-28 Read SEC document |
| December 28, 2016 Filed May 18, 2017 10:18 UTC | TELIX QSAM INC. qpwr · Entity 91566 | Purchaseoptions to purchase common stock · Derivative | 200,000 | $0.21 Strike: $0.21 | $42,000.00 |
DisclosureSEC source: 0001588395-17-000001 · primary_doc.xml · derivative · entry 1 Mayersohn Joel David · CIK 0001588395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: common stock · 200,000 shares Expires 2026-12-28 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.